Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × Gefitinib × Clear all

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03599518 2023-02-08

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

20 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02039674 2022-11-08

MK-3475-021

Phase 1/2 Completed

267 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02374645 2020-04-24

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01469000 2019-09-10

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

195 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Approved for marketing

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Approved for marketing

Carcinoma, Non-Small-Cell Lung

NCT03264794 2017-08-29

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Phase 4 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00059722 2016-08-24

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00770588 2016-02-08

INFORM

Phase 4 Completed

296 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00162318 2015-10-28

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01017874 2015-07-08

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3 Completed

236 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01602289 2015-06-08

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Phase 1 Completed

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma

NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00536107 2013-10-01

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 4 Terminated

14 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00090675 2013-01-29

IMAC/Herbst

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

Phase 3 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00608868 2012-09-28

SELINE

Phase 4 Completed

156 enrolled 14 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00478049 2012-06-06

ISTANA

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT01391260 2011-08-02

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00234468 2011-05-20

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00076388 2011-05-13

Iressa Versus Docetaxel (Taxotere)

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT00255489 2011-01-25

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00409006 2010-09-09

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Phase 2 Completed

70 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT00264498 2009-08-03

Phase II Iressa & Carbo/Gem in NSCLC

Phase 2 Completed

38 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00234442 2009-06-30

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Phase 2 Terminated

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00256711 2009-04-23

Phase II Iressa Versus Vinorelbine (INVITE)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00080340 2008-01-15

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT00252798 2007-12-19

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00333294 2007-12-19

Phase II Iressa + Irradiation Followed by Chemo in NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00252707 2007-12-18

Iressa 2nd Line Phase III Study in Japan

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung